Colorectal NeoplasiaNCT06333392
Total Underwater Colonoscopy (TUC) for Improved Colorectal Cancer Screening: A Randomized Controlled Trial
A study testing Total underwater colonoscopy and Conventional colonoscopy in people with Colorectal Neoplasia and Screening Colonoscopy, run by Vestre Viken Hospital Trust at 5 sites in 2 countries.
Trial summary
Colorectal cancer (CRC), the third most diagnosed cancer and second most common cause of cancer death. CRCs develop from precursors like adenomas (about 70% of CRCs) or serrated lesions (SSLs) (about 25-30% of CRCs). Read more about this study
- Who is it for?
- Ages 55 to 60 years
- Conditions the study is for
- Colorectal Neoplasia, Screening Colonoscopy, Colorectal Cancer
- What is being tested?
- Total underwater colonoscopy and Conventional colonoscopy
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,070 participants
- Where
- 5 sitesin 2 countries
- Study dates
- 23 Oct 2024to Jun 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- All individuals referred to colonoscopy after a positive FIT screening at the participating screening centres
Who cannot join
- Individuals with a CRC diagnosis within the last 10 years.
Trial locations and contacts
5 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
Thomas de Lange, MD, associate prof contact
5 sites in 2 countries
Norway4 sites, 4 recruiting
- Recruiting
Vestre Viken Health Trust, Bærum Hospital
Drammen, 3004
Anna Lisa Schult, MD PhD, 0047413930003, anschu@vestreviken.no
Stine Hvattum, MD
- Recruiting
Østfold Hospital Health Trust
Grålum, 1714
Dung H Nguyen, MD, 004769860000, dung.hong.nguyen@so-hf.no
- Recruiting
Akershus University Hospital Health Trust
Lørenskog, 1478
Jan Henrik Rydning, MD, 0047 67 96 00 00, jan.henrik.rydning@ahus.no
Stephan Brackmann
- Recruiting
Ullevål University Hospital Health Trust
Oslo, 0424
Ingrid M Mikalsen, MD, 004722118080, inmika@ous-hf.no
Marte L Høivik, MD PhD, m.l.hoivik@medisin.uio.no
Sweden1 site, 1 recruiting
- Recruiting
Sahlgrenska University Hospital, Gothenburg, Region Västra Götaland, Sweden, Department of Medicine, Geriatrics and Emergency Care Mölndal
Gothenburg
Thomas de Lange, Associate professor, +46702794054, thomas.de.lange@gu.se
About this study
Colorectal cancer (CRC), the third most diagnosed cancer and second most common cause of cancer death. CRCs develop from precursors like adenomas (about 70% of CRCs) or serrated lesions (SSLs) (about 25-30% of CRCs). Colonoscopy is the cornerstone in CRC screening, in screening programmes often as a work-up examination after a positive primary screening test such as faecal immunochemical test (FIT). Norway and Sweden have recently launched a nationwide faecal haemoglobin CRC screening programmes. Recently, both a Dutch and an Austrian study showed that SSL detection rate (SSLDR) is inversely correlated to CRC at follow-up. Consequently, improved SSLDR can reduce the risk of post-colonoscopy CRC. SSLs are typically located in the right colon. They are flat, with indistinctive boarders, and consequently easily missed or incompletely resected. A Norwegian study showed incomplete resection of 40% of proximal SSLs. The prevalence of SSLs is higher in women than in men, with women being on a threefold risk of developing CRC from SSLs. It seems like post-colonoscopy CRC more often is caused by SSLs than by adenomas. Total underwater colonoscopy (TUC) is a technique replacing conventional CO2 insufflation by water infusion to distend the lumen and visualise the mucosa during withdrawal of the colonoscope and simultaneously removal of water. There are several reasons to advocate TUC:
- SSLs will be more visible as they "float" on the submucosa and contract into the lumen, while full distension by gas stretches the mucosa, making detection of flat lesions more difficult.
- Water works like a magnifying lens, making detection and detailed characterisation of lesions easier.
- uEMR is eased.
- Improved bowel cleansing
Read more
The goal of this clinical trial is to compare colonoscopy outcomes for standard gas (CO2) insufflation and TUC during withdrawal in patients participating in colonoscopy in the Norwegian and Swedish colorectal cancer screening programme after a positive fecal immunochemical test.
The overarching research questions of the present trial is whether colonoscopy outcomes are improved when CO2 insufflation is replaced by TUC during withdrawal and whether the new technique reduces the ecological footprint of the colonoscopy examination.
The project has five main hypotheses:
- TUC is superior to the standard approach (CO2 withdrawal) regarding detection of proximal SSLs.
- TUC increases the rate of complete resection of lesions \>= 10mm.
- TUC reduces the rate of painful colonoscopies and vasovagal reactions.
- TUC reduces the health care costs by reduced use of single use accessories and reduced number of redundant colonoscopies to obtain polypfree colon.
- TUC reduces the carbon footprint by reduced use of single use accessories.
If TUC is superior to gas insufflation, the technique may be implemented rapidly since the technique is easy to learn. This study will increase endoscopy competence at participating centres. The centres are involved in national colonoscopy training programs, so the technique will quickly be passed on to other hospitals and screening centres.
The trial can be linked to three of the Global Goals:
- Good health and well-being: The increased detection and improved complete removal of sessile serrated lesions can subsequently decrease the risk of CRC and CRC mortality during follow-up. TUC will probably reduce the rate of painful procedures and vasovagal reactions and thus increase the acceptance of a screening programme. Consequently, the project can contribute significantly to improve screening effectiveness in Norway and Sweden, particularly in women (women have a higher risk for SSLs and a higher risk of colorectal cancer developing from this type of precursor).
- Gender equality: Women have a similar lifetime risk for CRC as men but less benefit of screening regardless of whether they are screened by sigmoidoscopy, FIT or colonoscopy. The reason is probably missed sessile serrated lesions in the proximal colon. If TUC improves SSLDR and complete lesion resection, this may lead to an equal benefit from CRC screening for women and men. Women have also a higher risk of discomfort and pain during colonoscopy than men. It has been shown that women prefer non-invasive screening modalities, potentially to avoid pain during colonoscopy, even if colonoscopy may be the most beneficial screening method for women. If TUC reduces the rate of painful colonoscopies, it can reduce women's barriers to attend screening.
- Responsible consumption and production: The TUC technique will also reduce the ecological footprint of colonoscopy activity due to reduced consumption of single use accessories and reduced number of colonoscopies to achieve polyp free colon. Furthermore, the cost for the health care system will be substantially reduced.
- Conditions
- Colorectal Neoplasia, Screening Colonoscopy, Colorectal Cancer, Colorectal Cancer Screening, Vasovagal Reaction
- Being tested
- Total underwater colonoscopy, Conventional colonoscopy
- Keywords
- colorectal cancer screening, screening colonoscopy, underwater colonoscopy
- Medical subject headings
- Colorectal Neoplasms, Syncope, Vasovagal
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Total underwater colonoscopyProcedure or surgery
one grooup will be randomized to receive a total underwater colonoscopy
Conventional colonoscopyProcedure or surgery
one group will be randomized to undergo a conventional colonoscopy with CO2 withdrawal
| Study group | Role | What they receive |
|---|---|---|
| Conventional colonoscopy (CO2) group | Active comparator | this groups receives conventional colonoscopy with CO2 withdrawal Receives: Procedure: Conventional colonoscopy |
| Total underwater colonoscopy (TUC) group | Experimental | This group receives total underwater colonoscopy Receives: Procedure: Total underwater colonoscopy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proximal sessile serrated lesion detection rate
The proportion of colonoscopies where at least one proximal SSL is detected
Measured: when histopathology report is clear, about 4 weeks after colonoscopy
Secondary outcomes (11)
Complete resection rate for lesions > 10mm
see above
Measured: 4 weeks after colonoscopy
Rate of painful procedures and vasovagal reactions
se above
Measured: during and immediately after colonoscopy
Leakage after colonoscopy
water leakage on the way home after colonoscopy
Measured: Questionnaire 1-7 days after colonoscopy
Detection rate for other neoplasia than SSL
see above
Measured: about 4 weeks after colonoscopy
Withdrawal time
see above
Measured: immediately after colonoscopy
Total procedure time
see above
Measured: immediately after colonoscopy
Bowel cleansing quality
with help of BBPS
Measured: immediately after colonoscopy
Complications
Significant bleedings and perforations
Measured: within 30 days after colonoscopy
Number of colonoscopies to achieve polyp free colon
see above
Measured: after last colonoscopy per patient
Single use accessories for the procedure
number of single use accesoires per colonoscopy
Measured: immediately after colonoscopy
Willingness to repeat colonoscopy
Willingness to repeat colonoscopy the same way if new colonoscopy is necessary
Measured: questionnaire 1-2 weeks after colonoscopy
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Mar 2024
- Study start23 Oct 2024
- Primary completionDec 2026 (estimated)
- Study completionJun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Colorectal NeoplasiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 1,070 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Vestre Viken Hospital Trust
- Sponsor type
- University, hospital or other
- Collaborators
- Ullevaal University Hospital, Sahlgrenska University Hospital, Ostfold Hospital Trust, University Hospital, Akershus
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06333392
- Sponsor's protocol ID
- TotalUnderwater_REK577567
- Status last verified
- Sep 2026
- First submitted
- 20 Mar 2024
- Last updated
- 4 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 4 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Total Underwater Colonoscopy (TUC) for Improved Colorectal Cancer Screening: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT06333392
- Acronym / sponsor ID
- TotalUnderwater_REK577567
- Conditions
- Colorectal Neoplasia, Screening Colonoscopy, Colorectal Cancer, Colorectal Cancer Screening, Vasovagal Reaction
- Keywords
- colorectal cancer screening, screening colonoscopy, underwater colonoscopy
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 1,070 participants (estimated)
- Lead sponsor
- Vestre Viken Hospital TrustUniversity, hospital or other
- Collaborators
- Ullevaal University Hospital, Sahlgrenska University Hospital, Ostfold Hospital Trust, University Hospital, Akershus
- Study start
- 23 Oct 2024 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Jun 2027 (estimated)
- First posted
- 27 Mar 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Colorectal cancer (CRC), the third most diagnosed cancer and second most common cause of cancer death. CRCs develop from precursors like adenomas (about 70% of CRCs) or serrated lesions (SSLs) (about 25-30% of CRCs). Colonoscopy is the cornerstone in CRC screening, in screening programmes often as a work-up examination after a positive primary screening test such as faecal immunochemical test (FIT). Norway and Sweden have recently launched a nationwide faecal haemoglobin CRC screening programmes. Recently, both a Dutch and an Austrian study showed that SSL detection rate (SSLDR) is inversely correlated to CRC at follow-up. Consequently, improved SSLDR can reduce the risk of post-colonoscopy CRC. SSLs are typically located in the right colon. They are flat, with indistinctive boarders, and consequently easily missed or incompletely resected. A Norwegian study showed incomplete resection of 40% of proximal SSLs. The prevalence of SSLs is higher in women than in men, with women being on a threefold risk of developing CRC from SSLs. It seems like post-colonoscopy CRC more often is caused by SSLs than by adenomas. Total underwater colonoscopy (TUC) is a technique replacing conventional CO2 insufflation by water infusion to distend the lumen and visualise the mucosa during withdrawal of the colonoscope and simultaneously removal of water. There are several reasons to advocate TUC:
- SSLs will be more visible as they "float" on the submucosa and contract into the lumen, while full distension by gas stretches the mucosa, making detection of flat lesions more difficult.
- Water works like a magnifying lens, making detection and detailed characterisation of lesions easier.
- uEMR is eased.
- Improved bowel cleansing
The goal of this clinical trial is to compare colonoscopy outcomes for standard gas (CO2) insufflation and TUC during withdrawal in patients participating in colonoscopy in the Norwegian and Swedish colorectal cancer screening programme after a positive fecal immunochemical test.
The overarching research questions of the present trial is whether colonoscopy outcomes are improved when CO2 insufflation is replaced by TUC during withdrawal and whether the new technique reduces the ecological footprint of the colonoscopy examination.
The project has five main hypotheses:
- TUC is superior to the standard approach (CO2 withdrawal) regarding detection of proximal SSLs.
- TUC increases the rate of complete resection of lesions \>= 10mm.
- TUC reduces the rate of painful colonoscopies and vasovagal reactions.
- TUC reduces the health care costs by reduced use of single use accessories and reduced number of redundant colonoscopies to obtain polypfree colon.
- TUC reduces the carbon footprint by reduced use of single use accessories.
If TUC is superior to gas insufflation, the technique may be implemented rapidly since the technique is easy to learn. This study will increase endoscopy competence at participating centres. The centres are involved in national colonoscopy training programs, so the technique will quickly be passed on to other hospitals and screening centres.
The trial can be linked to three of the Global Goals:
- Good health and well-being: The increased detection and improved complete removal of sessile serrated lesions can subsequently decrease the risk of CRC and CRC mortality during follow-up. TUC will probably reduce the rate of painful procedures and vasovagal reactions and thus increase the acceptance of a screening programme. Consequently, the project can contribute significantly to improve screening effectiveness in Norway and Sweden, particularly in women (women have a higher risk for SSLs and a higher risk of colorectal cancer developing from this type of precursor).
- Gender equality: Women have a similar lifetime risk for CRC as men but less benefit of screening regardless of whether they are screened by sigmoidoscopy, FIT or colonoscopy. The reason is probably missed sessile serrated lesions in the proximal colon. If TUC improves SSLDR and complete lesion resection, this may lead to an equal benefit from CRC screening for women and men. Women have also a higher risk of discomfort and pain during colonoscopy than men. It has been shown that women prefer non-invasive screening modalities, potentially to avoid pain during colonoscopy, even if colonoscopy may be the most beneficial screening method for women. If TUC reduces the rate of painful colonoscopies, it can reduce women's barriers to attend screening.
- Responsible consumption and production: The TUC technique will also reduce the ecological footprint of colonoscopy activity due to reduced consumption of single use accessories and reduced number of colonoscopies to achieve polyp free colon. Furthermore, the cost for the health care system will be substantially reduced.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Conventional colonoscopy (CO2) group | Active comparator | Procedure: Conventional colonoscopythis groups receives conventional colonoscopy with CO2 withdrawal |
| Total underwater colonoscopy (TUC) group | Experimental | Procedure: Total underwater colonoscopyThis group receives total underwater colonoscopy |
Who may qualify
- Ages
- 55 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- All individuals referred to colonoscopy after a positive FIT screening at the participating screening centres
Key exclusion criteria (1 listed)
- Individuals with a CRC diagnosis within the last 10 years.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Total underwater colonoscopyone grooup will be randomized to receive a total underwater colonoscopy | Procedure or surgery | Total underwater colonoscopy (TUC) group |
| Conventional colonoscopyone group will be randomized to undergo a conventional colonoscopy with CO2 withdrawal | Procedure or surgery | Conventional colonoscopy (CO2) group |
Primary outcome
Proximal sessile serrated lesion detection rate
Time frame: when histopathology report is clear, about 4 weeks after colonoscopy
The proportion of colonoscopies where at least one proximal SSL is detected
11 secondary outcomes
Complete resection rate for lesions > 10mm
Time frame: 4 weeks after colonoscopy
Rate of painful procedures and vasovagal reactions
Time frame: during and immediately after colonoscopy
Leakage after colonoscopy
Time frame: Questionnaire 1-7 days after colonoscopy
Detection rate for other neoplasia than SSL
Time frame: about 4 weeks after colonoscopy
Withdrawal time
Time frame: immediately after colonoscopy
Total procedure time
Time frame: immediately after colonoscopy
Bowel cleansing quality
Time frame: immediately after colonoscopy
Complications
Time frame: within 30 days after colonoscopy
Number of colonoscopies to achieve polyp free colon
Time frame: after last colonoscopy per patient
Single use accessories for the procedure
Time frame: immediately after colonoscopy
Willingness to repeat colonoscopy
Time frame: questionnaire 1-2 weeks after colonoscopy
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Sep 2026.
- Individual participant dataSharing planned: Yes
Related trials for Colorectal Neoplasia
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingObservational study
Pre- and On-treatment Multi-omics Profiling of Locally Advanced Rectal Cancer
Rectal Neoplasms
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 2
Tislelizumab in People With Colorectal Cancer
Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Thomas de Lange, MD, associate prof contact
5 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Total underwater colonoscopy and Conventional colonoscopy in people with Colorectal Neoplasia and Screening Colonoscopy, run by Vestre Viken Hospital Trust at 5 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in Norway, Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Anna Lisa Schult, MD, PhD (+47 67 80 94 00, anschu@vestreviken.no), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proximal sessile serrated lesion detection rate (time frame: when histopathology report is clear, about 4 weeks after colonoscopy). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Sep 2026.